RecruitingNot ApplicableNCT03117946

Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy


Sponsor

Centre Hospitalier Universitaire de Besancon

Enrollment

220 participants

Start Date

May 29, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how the immune system — specifically the cells that fight cancer — responds when lung cancer or head and neck cancer patients receive radiation and chemotherapy at the same time. **You may be eligible if...** - You have been diagnosed with non-small cell lung cancer, small cell lung cancer, or head and neck cancer (confirmed by a tissue biopsy) - You are scheduled to receive radiation and chemotherapy together as your first treatment - You are willing to sign a consent form **You may NOT be eligible if...** - You are scheduled for radiation alone, stereotactic radiation, or radiation given before and after chemotherapy (not at the same time) - You have already received radiation and chemotherapy together for a previous cancer - You are currently taking immunotherapy, chemotherapy, or other immune-suppressing medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiological samples

blood and tumor tissue sample


Locations(4)

CHU de Besançon

Besançon, France

Centre Georges François LECLERC

Dijon, France

Hôpital Nord Franche-Comté

Montbéliard, France

Institut Jean Godinot

Reims, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03117946


Related Trials